Torsdag 26 December | 15:05:33 Europe / Stockholm

Prenumeration

2023-02-27 08:48:00

Redeye leaves its comments on Idogen following its Q4 report. The company has paused its ongoing phase l/lla-trial and the financial position is stressed. We lower our fair value range accordingly.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/